When experience matters, Fargo is where it is at. In an expansive facility that has built a reputation for the most efficient clinical conduct and with more experience than any CRO, Fargo teams have worked on nearly every dosage form available.

Our Fargo facility conducts more than 250 early phase studies per year, across a wide range of study types including thorough QT, bioavailability/bioequivalence, first-in-human, single ascending dose, multiple ascending dose, drug-drug interaction, pharmacokinetic/pharmacodynamic, food effect, oral contraceptive, irritation and sensitization, vasoconstrictor, taste, and consumer use.

Key indications include: asthma, allergy, dermatitis, diabetes, hypercholesterolemia, hypertension, obesity, osteoarthritis, hyperlipidemia, hypogonadism, hypothyroidism, men’s health, obesity, osteoporosis, and women’s health.

Special populations include: patients with high cholesterol mild hypertensive, obese, postmenopausal women, smokers, and surgically sterile.

The facility features 544 beds; 120 ICU-style beds; 14 study units; on-site clinical laboratory; on-site licensed pharmacy; and leading expertise in pre-clinical and clinical dermatology research.
[back to top]

Looking for access to diverse, special populations? Miami will deliver, along with our specialized expertise in taking compounds from first-in-human through proof-of-concept.

Our Miami facility conducts more than 30 early phase studies per year, across a wide range of study types including first-in-human, single ascending dose, multiple ascending dose, bioavailability/bioequivalence, drug-drug interaction, and pharmacokinetic/pharmacodynamic.

Key indications include: diabetes, infectious disease, hypertension, obesity, renal, and pain management

Special populations include: obese, surgically sterile, postmenopausal women, healthy elderly, and smokers.

The facility features 137 beds; 17 ICU-style beds; two study units; on-site central laboratory; on-site pharmacy; and access to diverse, special populations.
[back to top]

Certain things are very important to our clients—rapid start-up, clinical conduct and scheduling flexibility. St. Louis has proven processes in these integral areas that make us leaders in every study type—for as few as five up to 180 participants.

Our St. Louis facility conducts more than 240 early phase studies per year, across a wide range of study types including bioavailability/bioequivalence, drug-drug interaction, first-in-human, single ascending dose, multiple ascending dose, controlled substance, dermal irritation, sensitization studies, and pharmacokinetic/pharmacodynamic.

Key indications include: dermatology, hyperlipidemia, hypercholesterolemia, dietary, nocturia, and heartburn.

Special populations include: obese, surgically sterile, postmenopausal women, healthy elderly, and smokers.

The facility features 520 beds; 10 study units; two ICU-style units with 60 hospital beds; eight units with 36 to 120 beds each; and is Emergency Management Response agency (EMRa) licensed, allowing for advanced life-support procedures.
[back to top]

For diabetes treatment, there is no other facility this experienced or equipped to meet your needs. Located on the Christus Santa Rosa Medical campus, our San Antonio clinic conducts simple to complex protocols in normal healthy, diabetic and obese participants.

Our San Antonio facility conducts more than 130 Phase I through Phase III studies per year, across a wide range of study types including bioavailability/bioequivalence, drug-drug interaction, first-in-human, single ascending dose, multiple ascending dose, pharmacokinetic/pharmacodynamic, and proof-of-concept.

Key indications include: type I & II diabetes, nephropathy, neuropathy, hyperlipidemia, hypogonadism, hypothyroidism, men’s health, obesity, osteoporosis, and women’s health

Recruitment database includes more than 36,000 participants among normal healthy and specific patient populations—and is adjacent to one of the largest diabetes practices in North America, with a daily visit schedule of more than 350 patients and approximately 30 new visitors.

The facility features 100 beds; 12 ICU-style beds; on-site 797 compliant pharmacy; particular diabetes expertise including leading research authorities; and extensive experience running glucose clamps and in mixed meal and glucose tolerance.

[back to top]

When you need a team that has worked on a wide range of indications in normal healthy and patient populations and has specialty expertise in allergy, asthma and more—look to Toronto.

Our Toronto facility conducts more than 50 early phase studies per year, across a wide range of study types including first-in-human, single ascending dose, multiple ascending dose, bioavailability/bioequivalence, drug-drug interaction, pharmacokinetic/pharmacodynamic, proof-of-concept, and positron emission tomography.

Key indications include: allergy, asthma, atopic dermatitis, anxiety and depression, pain management, and diabetes.

Special populations include: diabetics, postmenopausal women, and healthy elderly.

The facility features 76 beds; eight ICU-style beds; three study units; state-of-the-art testing tools for respiratory and pulmonary functions; Environmental Exposure Chambers – six chambers for efficacy assessment of allergy, asthma and ocular treatments; and three allergen challenge models.
[back to top]

Lab results that stand out. From labs that always fit in.
Cetero’s Bioanalytical laboratories in Houston, Texas and Toronto, Ontario, can most easily be described in somewhat impersonal, antiseptic terms: Extensive list of validated bioanalytical methods. Accurate, reliable, reproducible and compliant data. Relentless quality controls. On-time delivery. State-of-the-art technology.

But there’s more to it than that, because our laboratory professionals, like everyone at Cetero, are in the business of serving our clients’ needs and helping them accomplish their goals. You can count on us to stay focused on the end result as well as the multiple data points we so carefully develop.

Whether you are a generic drug developer or an innovator, a large pharmaceutical firm or an emerging biotech, our Bioanalytical laboratories have the experience and capacity to develop the data you need, and to turn it around quickly. (We analyze more than 650,000 samples every year.)

Cetero’s project managers will get to know you, your preferences, your compound or molecule, and the end results you’re looking for. They arrange communications the way you want them. They control our resources at every level, so they can pull in additional help if they see a bottleneck developing.

The flexibility to do what you need. The capacity to do it all, and deliver the results on time. That’s what makes Cetero’s Bioanalytical laboratories fit perfectly with your needs, whether you’re looking for standalone laboratory services or end-to-end early development studies.

Houston Bioanalytical Laboratory Capabilities and Technology
36,000 square feet.

Core Services
LC-MS/MS
• Method Development
• Method Transfer
• Method Validation
• Sample Analysis

Ligand Binding
• PK/Antigenicity
• Method Development
• Method Transfer
• Method Validation
• Sample Analysis

Biomarkers
• MSD kits
• Elisa kits
• Novel matrices

Custom Synthesis
• Standards
• Internal standards

Technology
5 Tomtec Liquid Handling Systems

LC-MS/MS
• 2 Sciex API 365 mass spectrometers
• 15 Sciex API 3000 mass spectrometers
• 8 Sciex API 4000 mass spectrometers
• 2 Sciex API 5000 mass spectrometers

Immunochemistry
• PK studies
• Antigenicity
• Biomarkers

ELISA and ECL Detection Techniques
• Meso scale discovery
–SECTOR® imager 2400
• Molecular devices
–SpectraMax® 340 PC384
• Plate washers
–1 BioTek Elx-405
–Nunc-ImmunoWash 12

Climate-Controlled Room
• Walk-in freezer style
• Redundant controls
• Temp. 22 ± 1C
• Humidity 50% ± 10%
[back to top]

Toronto Bioanalytical Laboratory Capabilities and Technology
15,000 square feet.

Core Services
LC-MS/MS
• Method Development
• Method Transfer
• Method Validation
• Sample Analysis

Ligand Binding
• PK/Antigenicity

–Method Development
–Method Transfer
–Method Validation
–Sample Analysis

Biomarkers
• MSD kits
• Elisa kits
• Novel matrices

Custom Synthesis
• Standards
• Internal standards

Technology

LC-MS/MS
• 4 Micromass Quattro Ultima
• 8 Sciex API 4000 Mass Spectrometers
• 2 Sciex API 5500 Mass Spectrometers

Robotics
• Three Tomtec quadras

Software
• Thermo Fisher Watson LIMS system

–Version 7.3.01

• Analyst

–Version 1.5

• MassLynx 4.1